The National Academies

The National Academies: What You Need To Know About Infectious Disease

What You Need To Know About Infectious Disease

Microbial Evolution and Co-Adaptation: A Tribute to the Life and Scientific Legacies of Joshua Lederberg (2009)

Dr. Joshua Lederberg—scientist, Nobel laureate, visionary thinker, and friend of the Forum on Microbial Threats—died on February 2, 2008. It was in his honor that the Institute of Medicine's Forum on Microbial Threats convened a public workshop on May 20-21, 2008, to examine Dr. Lederberg's scientific and policy contributions to the marketplace of ideas in the life sciences, medicine, and public policy. The resulting workshop summary, Microbial Evolution and Co-Adaptation, demonstrates the extent to which conceptual and technological developments have, within a few short years, advanced our collective understanding of the microbiome, microbial genetics, microbial communities, and microbe-host-environment interactions.

View This Source

Related Reports

Explore Other Topics

What do you know about infectious disease?

True or False: Major pharmaceutical companies have great interest in dedicating resources to the antibiotics market because these short-course drugs are more profitable than drugs that treat chronic conditions and lifestyle ailments, such as high blood pressure or high cholesterol.

  • Sorry, that’s incorrect.

    Drugs that treat chronic conditions and lifestyle ailments are more profitable. Modern medicine needs new kinds of antibiotics to treat drug-resistant infections, but antibiotic research and development are expensive, risky, and time-consuming.

  • Correct!

    Drugs that treat chronic conditions and lifestyle ailments are more profitable. Modern medicine needs new kinds of antibiotics to treat drug-resistant infections, but antibiotic research and development are expensive, risky, and time-consuming.